What is the best size descriptor to use for pharmacokinetic studies in the obese?
about
A Review of the Toxicologic Implications of ObesityA review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?Understanding and applying pharmacometric modelling and simulation in clinical practice and researchFractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.Hemodynamic effects of leg crossing and skeletal muscle tensing during free standing in patients with vasovagal syncope.Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.Hematological toxicity of carboplatin for gynecological cancer according to body mass index.Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersPopulation pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.Broad-spectrum β-lactams in obese non-critically ill patients.Comparison of 3 body size descriptors in critically ill obese children and adolescents: implications for medication dosing.Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.What is the right dose for children?Pharmacokinetics and drug dosing in obese children.Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics.Persistent organic pollutants and obesity: are they potential mechanisms for breast cancer promotion?Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patientsA phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumorsFat-free weight prediction in morbidly obese females.Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study.Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjectsPopulation pharmacokinetic studies in pediatrics: issues in design and analysis.Case-control study of drug monitoring of β-lactams in obese critically ill patients.Changes in antidepressant metabolism and dosing across pregnancy and early postpartumModeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol.Creatinine-based equations for the adjustment of drug dosage in an obese population.Antimicrobial dosing considerations in obese adult patients.Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.Lean body mass-based levothyroxine replacement in young athyrotic patients with differentiated carcinoma of thyroid.Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010.Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising eventsPopulation Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.The effects of obesity on drug pharmacokinetics in humans.
P2860
Q28082947-9C420014-F035-4F6D-9479-C82FE151167BQ28087744-6FB410EF-FAFD-4DBA-B543-D726172A3CF0Q28468334-D8FAA37D-AD11-4E0D-91F7-7A11B66AB651Q30395441-9098B8D4-CE43-4D68-A6A3-CD3ECE9A29CFQ33151909-92A0D037-2B60-4DC6-9029-D84A40A83AF6Q33400101-2549C295-5132-4E8B-9348-D409B246A16CQ33432963-50931C88-D2C5-4CB0-BDC8-D3219C81F02DQ33676387-667D4443-FAAB-4360-9817-ADBBEA039793Q33795058-7A2BC4E0-5D8F-4349-8AA3-83AF580837B8Q33839225-ED9489F7-1A95-4AA2-A0BE-6B5141C0DC0AQ33886796-C2DC8F4D-67DA-473D-B92E-1E2DB394D89FQ34075909-31332D8B-469B-493A-9557-74AC678D79B8Q34180493-DDEBD8E9-3C8D-466B-833A-44046585592BQ34476850-88865390-492E-4FA0-9EC9-7050C03EC5E9Q35053910-31D2ECFF-0E3C-4F8C-847A-34354BA6564CQ35077796-5FE1BC4D-031A-4A46-A462-5946FC3475ACQ35154969-FA8C8C62-51F1-481B-AEC9-7B7BEF85DD79Q35191383-E5D97780-91C8-44DD-89C6-D3384848E5C1Q35549459-49782789-CD34-42A0-974C-0759EF4764FFQ35602586-79B4A6DF-F189-46B8-9FE7-3C38735F76C1Q35762761-5F565911-849E-42D5-8528-FFF573566116Q35827649-284A15B6-5F94-4D06-8582-6638CD51A15DQ35878860-1CCF8C26-4B6C-4773-95B8-167CC6E79115Q35912649-57628428-CE76-4B74-B458-74A602144C57Q36341632-EC6D4D07-5D52-4635-83B2-BA872FE03F36Q36558332-000A2BB1-ACF7-4528-B4AB-654880A5475DQ36692162-975B9D59-30BC-46FA-B369-4E56E7201170Q36702459-01870037-CF8A-498F-A963-774065B5C301Q36727919-12AC0403-0D5B-45DF-B73B-FA553A9E0DA4Q36792991-1B20B2C5-9D01-4445-82A4-2949ECB963D8Q36802097-8B3EC9DA-DD12-452F-ADB6-7DB6E05C8A5BQ36892796-F3835765-FB26-4D03-8F6E-777ABCB16648Q36924693-8D89EA6B-B437-4E6F-BC0D-8A3FCD9738D2Q36930705-E0A87612-F1E9-4F44-BC79-E23DA1756C11Q37237006-613DA37E-B700-45F1-BCD4-341920EF48D1Q37246076-E3D7BE3B-658C-433D-8C7D-D458BD7DE422Q37358623-2EC09C37-9D32-4A77-8268-CE72497AC7BAQ37471067-17F49BEB-2F65-40D5-A10B-1A2E50F42C8EQ37538609-BF025793-07CA-4056-B27A-C5CEA030B5B4Q37854751-6EA572E5-6D76-47BC-A421-0F14C89151A3
P2860
What is the best size descriptor to use for pharmacokinetic studies in the obese?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
What is the best size descriptor to use for pharmacokinetic studies in the obese?
@ast
What is the best size descriptor to use for pharmacokinetic studies in the obese?
@en
type
label
What is the best size descriptor to use for pharmacokinetic studies in the obese?
@ast
What is the best size descriptor to use for pharmacokinetic studies in the obese?
@en
prefLabel
What is the best size descriptor to use for pharmacokinetic studies in the obese?
@ast
What is the best size descriptor to use for pharmacokinetic studies in the obese?
@en
P2860
P1476
What is the best size descriptor to use for pharmacokinetic studies in the obese?
@en
P2093
Bruce Green
P2860
P304
P356
10.1111/J.1365-2125.2004.02157.X
P407
P577
2004-08-01T00:00:00Z